Evidence map›Paper›PMID 41799139›Full record

ArticleACS omega2026

[

Bo Li, Sydney A Jackson, Amelia Stepniak, Peggy Birikorang, Dominic Menendez, Robert Edinger, Michael Pun, Charles M Laymon, Carolyn J Anderson, Gary Kohanbash and 1 more

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo LiDepartment of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States.ORCID https://orcid.org/0000-0003-2397-4492
Sydney A JacksonDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224, United States.
Amelia StepniakDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224, United States.
Peggy BirikorangDepartment of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States.
Dominic MenendezDepartment of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States.
Robert EdingerDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15224, United States.
Michael PunDepartment of Radiology, University of Missouri, Columbia, Missouri 65211, United States.
Charles M LaymonDepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224, United States.
Carolyn J AndersonDepartment of Radiology, University of Missouri, Columbia, Missouri 65211, United States.ORCID https://orcid.org/0000-0002-5663-282X
Gary KohanbashDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224, United States.
W Barry EdwardsDepartment of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States.ORCID https://orcid.org/0000-0002-6070-8778

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is one of the deadliest types of cancer that occurs in people of all ages; 15 months is the average survival time. While treatments for GBM are mostly unsuccessful, immunotherapy has the potential to be an effective strategy for glioblastoma. However, the immunosuppressive influence of tumor-associated myeloid cells (TAMCs) results in poor responses to immunotherapy. As TAMCs are CD11b-positive, the potential of a radiolabeled αCD11b diabody was investigated to assess immunosuppression mediated by TAMCs in an immunocompetent mouse model of glioblastoma. An αCD11b diabody (Db) was constructed with the VH and VL sequences of an αCD11b IgG that resulted in thermal stability and high affinity. αCD11b Db was conjugated with a cross-bridged chelator, CB-TE1K1P, through click chemistry. The resulting conjugate was radiolabeled with

Identifiers

PMID41799139
PMCPMC12961533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.